(Q36610995)

English

A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status

scientific article published on 24 July 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

author name string

H-C Jeung

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

S Y Rha

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

S J Shin

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

J B Ahn

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

S H Noh

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

J K Roh

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

H C Chung

7

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

language of work or name

0 references

publication date

24 July 2007

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

97

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

458-463

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360346

30 September 2017

Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360346

30 September 2017

Review of second-line chemotherapy for advanced gastric adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360346

30 September 2017

Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360346

30 September 2017

A systematic overview of chemotherapy effects in gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360346

30 September 2017

Phase II study of paclitaxel in pretreated advanced gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360346

30 September 2017

Evaluation of the prognostic factors in gastric cancer: the effect of chemotherapy on survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360346

30 September 2017

New developments in the treatment of gastric carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360346

28 June 2018

Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360346

20 September 2018

Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360346

20 September 2018

A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360346

20 September 2018

Successful initial treatment with weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin chemotherapy in advanced gastric cancer patients with disseminated intravascular coagulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360346

20 September 2018

Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360346

20 September 2018

Influence of preoperative performance status on survival time of patients with advanced gastric cancer following noncurative resection

1 reference

https://pubmed.ncbi.nlm.nih.gov/17653073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irinotecan, fluorouracil and folinic acid (FOLFIRI) as effective treatment combination for patients with advanced gastric cancer in poor clinical condition

1 reference

https://pubmed.ncbi.nlm.nih.gov/17653073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17653073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations

1 reference

https://pubmed.ncbi.nlm.nih.gov/17653073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17653073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Studies in prognostic factors relating to chemotherapy for advanced gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17653073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17653073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers. An effective and low-toxic regimen for patients with poor general condition

1 reference

https://pubmed.ncbi.nlm.nih.gov/17653073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17653073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17653073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/17653073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recurrence following curative resection for gastric carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17653073

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6603902

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36610995&oldid=2199085525"